Core Viewpoint - The company is exploring and proposing investments in the high-performance materials industry, which is experiencing significant growth globally [1] Group 1: Company Strategy - The company is actively seeking to acquire coating production lines, research and development equipment for high-performance materials, and related patents to capture market opportunities in Southeast Asia, particularly in China [1] - The company aims to leverage its experience from the production of its own brand "Yes!Star" S2 film cameras to enhance product quality and efficiency, with plans to invest in upgrading R&D equipment [1] Group 2: Industry Insights - The high-performance materials market is currently thriving, with continuous upward momentum [1] - The board anticipates that high-performance materials will initially be utilized in the oil and gas, hydrogen, and new energy sectors, with potential applications across various industries depending on suitability [2]

Core Viewpoint - The company is exploring and proposing investments in the high-performance materials industry, which is experiencing significant growth globally [1] Group 1: Company Strategy - The company is actively seeking to acquire coating production lines, research and development equipment for high-performance materials, and related patents to capture market opportunities in Southeast Asia, particularly in China [1] - The company aims to leverage its experience from the production of its own brand "Yes!Star" S2 film camera to enhance product quality and efficiency, with plans to invest in upgrading R&D equipment [1] Group 2: Industry Insights - The high-performance materials market is currently booming, with a continuous upward trend [1] - Coating technology is identified as a critical process in the production of high-performance materials, enabling the transformation of bulk materials into commercially viable products [1] - The initial applications of high-performance materials are expected to be in the oil and gas, hydrogen, and new energy sectors, with potential for use across various industries depending on suitability [2]

自願公告 業務最新消息 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 的表現，實際上創造出「全新」的複合材料。塗布是材料與環境之間的介面。透過此 介面的工程設計，我們能在不改變大宗材料本身的情況下，徹底改變其表現，往往 實現超乎尋常的成本效益。 本公告由巨星醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）自願 發表，旨在向本公司股東及潛在投資者提供有關本集團業務發展以及潛在業務策略 及方向的最新消息。 高性能材料業 本公司董事（「董事」）會（「董事會」）謹此提供最新消息，本公司現正探索及建議投資 於高性能材料業。該行業屬於製造分部，從事設計、建造及商業化在關鍵特性的表 現較傳統同類產品超出至少一個數量級的物質。 董事會注意到，全球的高性能材料市場現正蓬勃增長，升勢不斷。為 ...

截至月份: 2025年11月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 巨星醫療控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02393 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | 本月底法 ...

公司名稱: 巨星醫療控股有限公司 呈交日期: 2025年11月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02393 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | FF30 ...

Core Viewpoint - Giant Medical Holdings (02393.HK) experienced a significant intraday increase of over 17%, reaching a price of 0.153 HKD with a trading volume of 4.8978 million HKD [1] Group 1 - The stock price of Giant Medical Holdings rose by 17.69% during trading [1] - The trading volume for the stock was reported at 4.8978 million HKD [1]

Core Viewpoint - Giant Medical Holdings (02393) has seen a significant stock increase of 17.69%, reaching HKD 0.153, with a trading volume of HKD 4.8978 million following the announcement of a potential joint venture with New Genetron Holding Limited in Singapore [1] Group 1: Joint Venture Announcement - The company is considering establishing a joint venture with New Genetron Holding Limited in Singapore [1] - The proposed joint venture aims to develop operations in Indonesia, Malaysia, and Singapore [1] - A new entity will be registered in Indonesia, focusing on designing, constructing, and operating clinical molecular diagnostic laboratories centered on precision oncology [1] Group 2: Business Focus - The joint venture will provide advanced medical laboratories, including cancer screening and advanced genetic testing [1] - The goal is to assist doctors in early disease detection and tailor treatment plans for patients [1] - The focus will be on advanced molecular diagnostic services, utilizing cutting-edge laboratory tests to detect and understand diseases at the molecular level, particularly in the field of precision oncology [1]

Core Viewpoint - Giant Medical Holdings (02393) is considering establishing a joint venture with New Genetron Holding Limited in Singapore, focusing on advanced molecular diagnostics in oncology, particularly in Indonesia, Malaysia, and Singapore [1] Group 1: Company Developments - On October 20, Giant Medical Holdings announced plans for a joint venture that will involve setting up a new entity in Indonesia dedicated to designing, constructing, and operating clinical molecular diagnostic laboratories focused on precision oncology [1] - The proposed joint venture aims to provide advanced gene testing, including cancer screening, to assist doctors in early disease detection and tailor treatment plans for patients [1] Group 2: Industry Focus - The joint venture will concentrate on advanced molecular diagnostic services, utilizing cutting-edge laboratory tests to detect and understand diseases at the molecular level, particularly in the field of precision oncology [1] - The initiative is expected to establish in vitro diagnostic reagent and kit production facilities in Indonesia when appropriate, enhancing local healthcare capabilities [1]

Company News - China Mobile (00941.HK) reported a total operating revenue of 794.7 billion yuan for the first three quarters, a year-on-year increase of 0.4%, with a net profit of 115.4 billion yuan, up 4% [1] - As of September 30, communication service revenue was 683.1 billion yuan, a 0.8% increase year-on-year, while sales of products and others were 111.5 billion yuan, a decrease of 1.7% [1] - Mobile internet traffic increased by 8.3% year-on-year, with a mobile ARPU of 48.0 yuan [1] - Contemporary Amperex Technology Co., Ltd. (宁德时代) (03750.HK) achieved revenue of approximately 283.07 billion yuan from January to September, a year-on-year increase of 9.28%, with a net profit of approximately 49.03 billion yuan, up 36.2% [1] Financing and Buyback Dynamics - HSBC Holdings (00005.HK) repurchased 4.64 billion HKD worth of shares, totaling 4.5664 million shares, at prices ranging from 100.6 to 102.4 HKD [6] - Mengniu Dairy (02319.HK) repurchased shares worth 10.14 million HKD, totaling 700,000 shares, at prices between 14.37 and 14.52 HKD [6] - Lianyi Technology (09959.HK) repurchased shares worth 743.93 million HKD, totaling 2.45 million shares, at prices ranging from 2.97 to 3.07 HKD [7]

Core Viewpoint - The company is considering establishing a joint venture with New Genetron Holding Limited in Singapore, focusing on developing advanced molecular diagnostic laboratories in Indonesia, Malaysia, and Singapore, particularly in precision oncology [1][3]. Group 1: Joint Venture Details - The proposed joint venture will register a new entity in Indonesia, specializing in designing, constructing, and operating clinical molecular diagnostic laboratories with a focus on precision oncology [1]. - The joint venture aims to provide advanced genetic testing, including cancer screening, to assist doctors in early disease detection and personalized treatment plans [1][2]. Group 2: Product Offerings - Key products include early cancer screening (e.g., HCCscreen and HCCscan for liver cancer), comprehensive genomic analysis, minimal residual disease (MRD) monitoring, and non-invasive prenatal testing (NIPT) [2]. - Initial operations will focus on laboratory-developed tests (LDT) and will gradually expand to local manufacturing and broader insurance coverage [2]. Group 3: Strategic Partnerships - The joint venture is expected to establish clinical and business partnerships with renowned hospitals and medical institutions in Indonesia for sample collection, product validation, and early clinical applications [3]. - A joint board and management team will be formed to oversee strategic operations, ensuring compliance with local health regulations [3]. Group 4: Market Potential and Growth - The establishment of the joint venture is anticipated to accelerate the company's development in the rapidly evolving diagnostic market, diversify revenue sources, and enhance competitive advantages in healthcare service delivery [4]. - The increasing demand for quality diagnostics in Indonesia, improved insurance coverage, and favorable demographics create significant growth prospects in the healthcare sector [4].